A PHASE 3, MULTI CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ORAL OZANIMOD AS MAINTENANCE THERAPY FOR MODERATELY TO SEVERLY ACTIVE CROHN's DISEASE

Trial Profile

A PHASE 3, MULTI CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ORAL OZANIMOD AS MAINTENANCE THERAPY FOR MODERATELY TO SEVERLY ACTIVE CROHN's DISEASE

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Jul 2018

At a glance

  • Drugs Ozanimod (Primary)
  • Indications Crohn's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 14 May 2018 Planned End Date changed from 31 Jul 2021 to 31 Jan 2021.
    • 14 May 2018 Planned primary completion date changed from 31 Jul 2021 to 31 Jan 2021.
    • 09 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top